Generic Effexor XR Availability

Effexor XR is a brand name of venlafaxine, approved by the FDA in the following formulation(s):

EFFEXOR XR (venlafaxine hydrochloride - capsule, extended release;oral)

  • Manufacturer: WYETH PHARMS INC
    Approval date: October 20, 1997
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [RLD] [AB]

Has a generic version of Effexor XR been approved?

A generic version of Effexor XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Effexor XR and have been approved by the FDA:

venlafaxine hydrochloride capsule, extended release;oral

  • Manufacturer: ANCHEN PHARMS
    Approval date: March 16, 2012
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: April 14, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: May 6, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: June 1, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: ORCHID HLTHCARE
    Approval date: July 11, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: TEVA
    Approval date: June 28, 2010
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: TORRENT PHARMS LLC
    Approval date: June 1, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: VALEANT BERMUDA
    Approval date: April 15, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: WOCKHARDT
    Approval date: April 14, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: April 14, 2011
    Strength(s): EQ 37.5MG BASE [AB], EQ 75MG BASE [AB], EQ 150MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Effexor XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Venlafaxine for the treatment of generalized anxiety disorder
    Patent 5,916,923
    Issued: June 29, 1999
    Inventor(s): Rudolph; Richard L. & Upton; G. Virginia
    Assignee(s): American Home Products Corporation
    This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia iervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, aakyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
    Patent expiration dates:
    • December 28, 2013
      ✓ 
      Pediatric exclusivity
  • Extended release formulation of venlafaxine hydrochloride
    Patent 6,274,171
    Issued: August 14, 2001
    Inventor(s): Sherman; Deborah M. & Clark; John C. & Lamer; John U. & White; Steven A.
    Assignee(s): American Home Products Corporation
    This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
    Patent expiration dates:
    • March 20, 2017
    • September 20, 2017
      ✓ 
      Pediatric exclusivity
  • Extended release formulation of venlafaxine hydrochloride
    Patent 6,403,120
    Issued: June 11, 2002
    Inventor(s): Deborah M.; Sherman & John C.; Clark & John U.; Lamer & Steven A.; White
    Assignee(s): Wyeth
    This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
    Patent expiration dates:
    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF SOCIAL ANXIETY DISORDER
    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
    • September 20, 2017
      ✓ 
      Pediatric exclusivity
  • Extended release formulation of venlafaxine hydrochloride
    Patent 6,419,958
    Issued: July 16, 2002
    Inventor(s): Deborah M.; Sherman & John C.; Clark & John U.; Lamer & Steven A.; White
    Assignee(s): Wyeth
    This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
    Patent expiration dates:
    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF SOCIAL ANXIETY DISORDER
    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
    • September 20, 2017
      ✓ 
      Pediatric exclusivity
  • Treatment using venlafaxine
    Patent 6,444,708
    Issued: September 3, 2002
    Inventor(s): Richard L.; Rudolph & Albert T.; Derivan & G. Virginia; Upton
    Assignee(s): Wyeth
    This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: in which A is a moiety of the formula where the dotted line represents optional unsaturation; R1 is hydrogen or alkyl; R2 is alkyl; R4 is hydrogen, alkyl, formyl, or alkanol; R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
    Patent expiration dates:
    • December 28, 2013
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web4)